

MAXIOM GROUP DESIGNS AND IMPLEMENTS WINNING IT STRATEGY FOR NOVAVAX

Plan Assists in Preparing for Commercial Launch

Waltham, MA, June 8, 2010 – [Maxiom Group](#), a leading operations and IT consulting firm exclusively serving the life sciences industry, is assisting Novavax in preparing for commercial launch through the rapid development of an IT strategy and roadmap, system selections, and project oversight. [Novavax, Inc.](#) (Nasdaq: NVAX) is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1.

According to Fred Driscoll, CFO at Novavax, “Maxiom Group has been an excellent partner in helping us quickly determine a winning IT strategy and 3-5 year implementation roadmap, and rapidly drive through an ERP selection process to find the right solution for our requirements. We plan to continue to work with Maxiom Group as we select and implement additional enterprise systems”.

John Lyons, Maxiom Group Vice President commented. “Emerging life science companies typically find IT prioritization and planning very difficult. Utilizing our methods and approach, combined with our knowledge of the life science industry, enables us to create a clear 3-5 year plan, fostering timely client decisions.”

Through this work with Novavax, Maxiom Group continues the process of helping emerging companies transform from research and development organizations to efficient and successful commercial companies by planning and implementing IT solutions required for product launch.

Download the Maxiom Group datasheet [here](#) to learn more about transforming IT to achieve commercial success.

ABOUT MAXIOM GROUP

Maxiom Group is a leading strategic business and IT consulting firm exclusively serving the life sciences industry. We help transform emerging, established and mature biotechnology, pharmaceutical and medical device companies at each stage of their life cycle by solving mission critical business issues. From drug discovery and development, to clinical trials, to commercial launch and sustained market leadership, Maxiom Group clients rely on our unique focus, insight and approach. For more information please visit www.maxiomgroup.com.

ABOUT NOVAVAX

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. For more information please visit www.novavax.com/.

Contact Information:

Carol Fassino

Maxiom Group

<mailto:cfassino@maxiomgroup.com>

781/250-4892